Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A1250 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.


Download subscription form here



Latest News !

Dr Boreham's Crucible: Orthocell

Biotech Daily Editorial: Doing The Deal

Merck Pays Viralytics $502m For Cavatak Cancer Immontherapy

Varian Offers $1.6b For Sirtex

2017 - The Year In Review

Biotech Daily Editorial - Selective Briefings 

Biotech Revenue Up 194% In 8 Years To $1.4b

WEHI $405m+ Canada Venetoclax For Cancer Deal

10-Year BDI-40 Up 80%, ASX200 Down 9% Big Caps Up 270%

Novartis Buys Spinifex For $916m



February BDI-40 Up 4.5%, ASX200 Down 0.3%,
Big Caps Break $100 billion

 Vitralytics Up 136%, Uscom 36%; Airxpanders Down 27%, Benitec 15%


Mar 1, 2018

The collective market capitalization of the three Big Caps of Cochlear, CSL and Resmed has broken through the $100 billion mark for the first time.
In February, CSL added $7,576 million or 11.4 percent - on yet another excellent half-year report - to take its market capitalization to $73,797 million, with Cochlear up 5.9 percent to $10,583 million.
The Big Caps (which are not included in the BDI-40) improved 37.0 percent in the 12 months to February 28, but Resmed slipped 1.4 percent from last month’s record high to $17,576 million.
The Biotech Daily Top 40 Index (BDI-40) was almost as good over the 12-months to February 28 - up 28.4 percent compared to the ASX200 up 5.3 percent, with the Nasdaq Biotechnology Index (NBI) up 9.4 percent (see charts below).
For the month of February, the BDI-40 improved 4.5 percent, the Big Caps were up 8.4 percent and the NBI fell 5.3 percent, while the ASX200 slipped 0.3 percent.
February saw a plethora of small rises and falls, but Viralytics added $266 million to the index following last week’s $502 million Merck acquisition, and Mesoblast improved $208 million on positive data from its trial of MSC-100-IV or, remestencel-l, for graft versus host disease on the same day (BD: Feb 22, 2018).
Eighteen of the BDI-40 companies were up, 18 fell and four were unchanged.
Viralytics was the best, up 136.4 percent to $461 million, followed by Uscom up 35.7 percent to $38 million, Mesoblast (32.8%), Actinogen (22.6%), Neuren (18.2%), Pharmaxis (17.4%), Bionomics (14.4%) and Dimerix (13.3%).
Airxpanders led the falls, down 26.9 percent to $141 million, followed by Benitec (14.9%), ITL (14.7%), Compumedics (13.5%), Reva (12.5%), Oncosil (11.25%), Ellex (11.1%), Starpharma (8.5%) and Nanosonics (6.4%).
Outside the BDI-40, Cynata and Patrys have made serious progress, up 28.4 percent to $104 million and 115.8 percent to $41 million, respectively, with strong share price improvements for Bioxyne, Botanix, Invion, Invitrocue, Medlab Clinical and Noxopharm
The 15 companies in Cannabis Corner fell 9.3 percent in February to $1,428 million, with Tasmanian Poppy Industries down 35.2 percent to $118 million.
In the US, Queensland’s Protagonist retreated 23.1 percent from last month’s record high of $581 million to $447 million, with Israel’s Redhill up 7.9 percent to $177 million, while Vaxart, which is half-held by Aviragen (formerly Melbourne’s Biota) shareholders, was down a further 10.7 percent to $25 million.
BDI-40 v S&P ASX200 Jun 30, 2006 to Feb 28, 2018 
BDI-40 v S&P ASX200 Feb 28, 2017 to Feb 28, 2018 
Big Caps (Cochlear, CSL, Resmed) Year To Feb 28, 2018


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At Feb 28, 2018


* Biotech Daily editor, David Langsam, owns shares in Acrux, Benitec, Mesoblast, Nanosonics, Optiscan,
   Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: